BLU-852 / Roche, Sanofi - LARVOL DELTA

Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021 (PRNewswire) - "BLU-222:...At AACR, preclinical data highlighted a set of potent and selective CDK2 inhibitors designed by Blueprint Medicines...BLU-222, which is expected to enter clinical development in the first half of 2022...Data presented at AACR highlighted a set of potent and highly selective MAP4K1 inhibitors designed by Blueprint Medicines, including BLU-852...BLU-852 under the company's cancer immunotherapy collaboration with Roche, with Phase 1 trial initiation anticipated in 2022."

New P1 trial • New trial • Preclinical • Oncology • Solid Tumor

Blueprint Medicines Reports Third Quarter 2021 Financial Results (PRNewswire) - "The company expects to achieve the following near-term milestones: (i) Initiate a Phase 1 trial of BLU-852, a MAP4K1 inhibitor for the treatment of advanced cancers, in 2022. BLU-852 is the first development candidate nominated under Blueprint Medicines' cancer immunotherapy collaboration with Roche."

New P1 trial • Oncology